US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Australian Clinical Labs Limited (ACL) 銘柄情報

Australian Clinical Labs Limited (ACL)

2.07

0.01

(0.49%)

終了 6月9日 3:00PM

Australian Clinical Labs Limited (ACL) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.07

( 0.49% )

買値

2.06

売値

2.08

出来高

382,022

2.045 日の範囲 2.08

1.8325 52 週間の範囲 2.97

時価総額

前日終値

2.06

始値

2.05

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 717,112

発行済株式数

186,455,074

配当利回り

0.13 (5.58%)

PER

14.61

1 株当たり利益 (EPS)

0.14

歳入

737.49M

純利益

26.31M

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematol... Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.clinicallabs.com.au

本社

Clayton, Australia

設立

2026

Australian Clinical Labs Limited is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker ACL. The last closing price for Australian Clinical Labs was AUD2.06. Over the last year, Australian Clinical Labs shares have traded in a share price range of AUD 1.8325 to AUD 2.97.

Australian Clinical Labs currently has 186,455,074 shares in issue. The market capitalisation of Australian Clinical Labs is AUD385.96 million. Australian Clinical Labs has a price to earnings ratio (PE ratio) of 14.61.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.05	2.47524752475	2.02	2.09	1.97	473319	2.03464012	DE
4	0.135	6.97674418605	1.935	2.09	1.8325	644463	1.95458051	DE
12	0.03	1.47058823529	2.04	2.11	1.8325	710462	1.98941662	DE
26	-0.75	-26.5957446809	2.82	2.86	1.8325	698009	2.24022719	DE
52	-0.72	-25.8064516129	2.79	2.97	1.8325	759994	2.4746472	DE
156	-1.38	-40	3.45	3.855	1.8325	706831	2.80824697	DE
260	-1.73	-45.5263157895	3.8	6.39	1.8325	717880	3.35527089	DE

ACL - Frequently Asked Questions (FAQ)

What is the current Australian Clinical Labs Limited share price?

The current share price of Australian Clinical Labs Limited is AUD 2.07

How many Australian Clinical Labs Limited shares are in issue?

Australian Clinical Labs Limited has 186,455,074 shares in issue

What is the market cap of Australian Clinical Labs Limited?

The market capitalisation of Australian Clinical Labs Limited is AUD 385.96M

What is the 1 year trading range for Australian Clinical Labs Limited share price?

Australian Clinical Labs Limited has traded in the range of AUD 1.8325 to AUD 2.97 during the past year

What is the PE ratio of Australian Clinical Labs Limited?

The price to earnings ratio of Australian Clinical Labs Limited is 14.61

What is the cash to sales ratio of Australian Clinical Labs Limited?

The cash to sales ratio of Australian Clinical Labs Limited is 0.52

What is the registered address of Australian Clinical Labs Limited?

The registered address for Australian Clinical Labs Limited is 1868-1892 Dandenong Road, Clayton, Victoria, 3168

What is the Australian Clinical Labs Limited website address?

The website address for Australian Clinical Labs Limited is www.clinicallabs.com.au

Which industry sector does Australian Clinical Labs Limited operate in?

Australian Clinical Labs Limited operates in the Medical Diagnostics & Screening sector

Madguppy

Madguppy 2分前

May be a post to check out in the short term.

https://x.com/scottmi65383320/status/2064163222131995113?s=20

Monksdream

Monksdream 2分前

TOP 15
https://www.advfn.com/markets/nasdaq/premarket

RIGATONI

RIGATONI 3分前

Dip here into the .27s, may be a nice buy-back area ~Rig

AMOTE1

https://www.kraiglabs.com/kraig-biocraft-laboratories-sets-new-all-time-production-record-delivering-nearly-2-5-metric-tons-of-recombinant-spider-silk-in-single-production-cycle/

Jake731

Jake731 5分前

Good morning all.

TPTW-EM……!!!!!!!

VuMe Live 😎😎😎

jopo

Seem's, Webull is working good for you.

RIGATONI

RIGATONI 5分前

Good morning! ~Rig

jimmybob

jimmybob 7分前

$RDDT with some pre-market love

US Market News

US Market News 8分前

Fresh Del Monte Produce Inc. Announces Name Change to Del Monte Corporation and NYSE Ticker Symbol Change to “DMC”June 9, 2026 6:30 AM
Business Wire Reflects the Company's Expanded Role as Global Owner of the Del Monte® Brand; Ticker Symbol Change Effective Jun

US Market News

US Market News 8分前

Four-Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long-Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)June 9, 2026 6:30 AM
Business Wire Persistently Low Target Lesion Failure and No New Cardiac-Rel

US Market News

US Market News 8分前

Uxin to Report First Quarter 2026 Financial Results on June 16, 2026June 9, 2026 6:30 AM
PR Newswire (US) class="legendSpanClass"BEIJING, class="legendSpanClass"June 9, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq:

SovereignNinja5

SovereignNinja5 9分前

Vascepa still holds roughly 50% of the total icosapent ethyl market even with zero sales reps on the ground and after losing preferred status at CVS. That’s not a dead product — that’s a product that’s been surviving on brand loyalty and prescriber habit while the company was busy firing its commerc

US Market News

US Market News 9分前

Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper Kobuk Mineral Projects in AlaskaJune 9, 2026 6:30 AM
PR Newswire (US) class="legendSpanClass"VANCOUVER, BC, class="legendSpanClass"June 9, 2026 /PRNewswire/

CA Market News

CA Market News 9分前

Critical Elements Announces the Start of A 10,000-Meter Summer Drill Program at Rose WestJune 9, 2026 6:30 AM
ACCESS NewswireMONTRÉAL, QUÉBEC / ACCESS Newswire / June 9, 2026 / Critical

Mark

$GLE watching off of $HXHX pop

Mark

$ADTX .04 keep on watch, HRT Financial filed a form 4 last night for 1.6m shares, they also have a Nasdaq hearing panel scheduled for Jun 11. This HRT financial seems to be sending stuff lately.

DTGoody

DTGoody 11分前

Good Morning! Basically yes on that .04 cents. That valuation is not out of the question once multiple military contracts are secured and we get ITAR compliant.

nowwhat2

nowwhat2 11分前

However, it certainly isn't unthinkable (PM's ARE still hugely under-owned)

https://www.youtube.com/watch?v=-5yiZ_4XfQ0

https://investorshub.advfn.com/uimage/uploads/2026/6/8/rtsgasilver_june_8_10y_MY_OVAL_VS_STRAIGHT_UP.jpg

https://investorshub.a

NASDAQ2020

NASDAQ2020 13分前

Locked $ Loaded !!!!!!!!!!!!!! For THE Buyout !!!!!!!!!!!!

https://www.secform4.com/insider-holders/1053369.html#:~:text=Insider%20Holders%20&%20Insider%20Ownership%20%2D%20ELITE%20PHARMACEUTICALS%20INC%20(ELTP),not%20adjusted%20for%20stock%20split.
Bullish

EL

ollik78

ollik78 15分前

💵💵💵🛩️ feel so 🥳😎 …

EHRjunkie

EHRjunkie 16分前

About Halberds IP:

Halberd holds the exclusive rights to 5 granted U.S. Patents:
US9,216,386 (expiration date: 2030-03-16)
US8,758,287 (expiration date: 2030-01-12)
US11,186,629 (expiration date: 2038-03-23)
US8,865,733 (expiration date: 2030-06-05)

TheBurn

TheBurn 16分前

https://x.com/NxGen_Brands/status/2064152466116272492?s=20

stock_observer_77

stock_observer_77 18分前

Australian Clinical Labs

Rainbow Small and Medium...

Old Market Capital

Callable Zero Coupon Not...

Calithera Biosciences (EM)

Callable Zero Coupon Not...

Ci Canadian Income and G...

Agf European Equity Clas...

Rogers Communications

Ci Corporate Bond Class ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。